Tadalafil appears to effectively improve sexual function with acceptable side effects in diabetic patients with erectile dysfunction, according to a study. However, older patients fare better with the daily low-dose than the on-demand high-dose protocol.
Penile low-intensity shockwave treatment (LIST) is effective in men with erectile dysfunction (ED), but its efficacy gradually decreases with time, a recent study has shown. Moreover, those with diabetes are more likely to experience earlier failure of treatment.
A 70-year-old male with a history of diabetes, hyperlipidaemia and hypertension managed with atenolol presented to his family physician with lower urinary tract symptoms (LUTS). He was prescribed terazosin. Over the course of a year he noticed worsening erectile dysfunction (ED) with difficulty maintaining a hard erection until orgasm.
Erectile dysfunction (ED) is a common condition defined as the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance.1 It is one of the most common complaints in men’s sexual medicine, affecting both physical and psychosocial health and having a significant impact on the patient and partner’s quality of life.1 Moreover, ED is commonly associated with other comorbid conditions, including hypertension, dyslipidaemia and diabetes mellitus.1
Evaluation of ED should include a detailed medical and sexual history of the patient. 1 A discussion of the patient and partner’s preference and treatment goals is essential to better tailor treatment and improve patient satisfaction and adherence to treatment.2 Lifestyle modification and management of risk factors should precede pharmacotherapy, while first-line treatment with oral phosphodiesterase type 5 inhibitors (PDE5i) is well established for the management of patients with ED.1
Use of phosphodiesterase-5 (PDE5) inhibitors
following a first myocardial infarction (MI) may reduce the risk of
long-term adverse outcomes, including mortality and heart failure
hospitalization, in a dose-dependent fashion, according to a Swedish study.
Erectile dysfunction may potentially be associated with gout, a new systematic report and meta-analysis reveals. However, the low quality and high degree of heterogeneity among the studies included reduce the certainty of this conclusion.
A dual-hormone artificial pancreas (DAP) with a rapid delivery of insulin and pramlintide in a fixed ratio improves glycaemic control and reduces glucose variability in adults with type 1 diabetes (T1D) compared with first-generation artificial pancreas delivering insulin alone, according to a study presented at ADA 2018.
More intensive lowering of LDL-C levels was associated with a progressively greater survival benefit than less intensive approach, when the baseline LDL-C levels were ≥100 mg/dL, reveals a meta-analysis of 34 randomized trials.
Switching from thiazide diuretic to ipragliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, leads to improvements in metabolic parameters and body mass composition without affecting blood pressure in type 2 diabetes (T2D) patients, a recent study has found.